TY - JOUR
T1 - Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post–lumbar puncture headache
AU - Stüve, Olaf
AU - Cataldi, Fabio
AU - Pradhan, Vivek
AU - Gorelick, Kenneth J.
N1 - Funding Information:
This study was sponsored by Pfizer (Protocol Number: A7281008).
Publisher Copyright:
© 2017
PY - 2017/9/15
Y1 - 2017/9/15
N2 - The pathogenesis of post–lumbar puncture headache (PLPH) has remained unclear. A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594). PF-00547659 is a human monoclonal antibody that binds to mucosal addressin–cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. The incidence of a PLPH was 35% after the initial lumbar puncture, and 26% following the second lumbar puncture. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy. Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.
AB - The pathogenesis of post–lumbar puncture headache (PLPH) has remained unclear. A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594). PF-00547659 is a human monoclonal antibody that binds to mucosal addressin–cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. The incidence of a PLPH was 35% after the initial lumbar puncture, and 26% following the second lumbar puncture. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy. Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.
UR - http://www.scopus.com/inward/record.url?scp=85021742392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021742392&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2017.06.011
DO - 10.1016/j.jneuroim.2017.06.011
M3 - Article
C2 - 28778448
AN - SCOPUS:85021742392
SN - 0165-5728
VL - 310
SP - 69
EP - 71
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
ER -